Privately-held Recludix Pharma has agreed a deal with French pharma major Sanofi to develop and commercialize oral small molecule STAT6 (signal transducer and a 21 July 2023
Dermatology specialist Journey Medical (Nasdaq: DERM) has announced positive topline results from two Phase III trials of its rosacea candidate, DFD-29, a formu 11 July 2023
Spanish skincare specialist Almirall has announced positive results from a real-world study of Ilumetri (tildrakizumab) at the 25th World Congress of Dermatolog 7 July 2023
The Johnson & Johnson subsidiary Janssen has announced positive topline results from its Phase IIb FRONTIER 1 trial of the first and only oral interleukin-23 re 5 July 2023
US drug major Bristol Myers Squibb’s Sotyktu (deucravacitinib), a once-daily oral tablet, has been recommended for use on the National Health Service (NHS) in E 28 June 2023
A commercial stage biopharmaceutical R&D company, focused on the development of products that address the medical challenges in the therapeutic area of anti-infectives.